NCT06859515 A Long-term Follow up Study of EXG102-031 in Participants With wAMD
| NCT ID | NCT06859515 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangzhou Jiayin Biotech Ltd |
| Condition | Wet Age-related Macular Degeneration |
| Study Type | OBSERVATIONAL |
| Enrollment | 42 participants |
| Start Date | 2025-03-13 |
| Primary Completion | 2030-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 42 participants in total. It began in 2025-03-13 with a primary completion date of 2030-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.
Eligibility Criteria
Inclusion Criteria: 1. Previously received treatment with EXG102-031 in the study (EXG102-031-111); 2. Paticipantes are informed consent and willingness to follow protocol procedures. Exclusion Criteria: 1\. Paticipantes are unwilling or unable to participate in long-term follow-up
Contact & Investigator
Mingwei ZHAO, PhD
PRINCIPAL INVESTIGATOR
Peking University People's Hospital
Frequently Asked Questions
Who can join the NCT06859515 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Wet Age-related Macular Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06859515 currently recruiting?
Yes, NCT06859515 is actively recruiting participants. Contact the research team at sarayang@exegenesisbio.com for enrollment information.
Where is the NCT06859515 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06859515 clinical trial?
NCT06859515 is sponsored by Guangzhou Jiayin Biotech Ltd. The principal investigator is Mingwei ZHAO, PhD at Peking University People's Hospital. The trial plans to enroll 42 participants.